Evaluation of SARS-CoV2 antibody Rapid Diagnostic Test kits (RDTs) and Real Time-Polymerase Chain Reaction (Rt-PCR) for COVID-19 Diagnosis in Kaduna, Nigeria

Ige, O; As, Buru; Tz, Lamido; Mohammed, Trifa M.; Dogara, Livingstone Gayus; Halima, B. M.; Reward, A; Samuel, I; Grace, not provided

doi:10.1101/2020.11.24.20231324

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, Nigeria validated it during the screening of youth corps before their admission into the compulsory one-year national service [ 12 ]. Ige et al reported that although COVID-19 RDTs have lower sensitivity and specificity, they have proven useful in scaling up Nigeria’s COVID-19 testing system especially in schools, congregations, and hard-to-reach areas [ 13 ]. However, it is yet to be determined if the low sensitivity of RDTs contributed to the lower COVID-19 incidence in Nigeria.…”

Section: Rapid Diagnostic Testsmentioning

confidence: 99%

“…However, it is yet to be determined if the low sensitivity of RDTs contributed to the lower COVID-19 incidence in Nigeria. COVID-19 testing using RDTs should be conducted by qualified health care personnel while adhering strictly to COVID-19 protocols to avoid technical errors and further community spread of the SARS-CoV-2 [ 13 ].…”

Section: Rapid Diagnostic Testsmentioning

confidence: 99%

See 1 more Smart Citation

Nigeria’s race to zero COVID-19 cases: True disease burden or testing failure?

et al. 2021

View full text Add to dashboard Cite

Section: Rapid Diagnostic Testsmentioning

confidence: 99%

Section: Rapid Diagnostic Testsmentioning

confidence: 99%

Nigeria’s race to zero COVID-19 cases: True disease burden or testing failure?

et al. 2021

View full text Add to dashboard Cite

“…RDTs are cheaper and provide a faster TAT compared to the PCR, albeit with lower sensitivity and speci city. (30) RDTs have proven useful in scaling up SARS-CoV-2 laboratory testing capacity in Nigeria especially in closed population. The proportion of tests conducted with RDTs in Nigeria was observed to gradually increase as the pandemic progressed and was up to 15% by the end of September, 2021.…”

Section: Discussionmentioning

confidence: 99%

Strategies for rapid scale up of laboratory capacity in a public health emergency in a resource-constrained setting: the SARS-CoV-2 Nigeria response experience

Bello

Adebowale

Dairo

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Sufficient laboratory capacity is vital to containing infectious diseases outbreaks. This study was conducted to assess SARS-CoV-2 testing performance, the strategies adopted to scale up laboratory testing capacity, and to highlight challenges and lessons learnt in Nigeria’s response to COVID-19 pandemic regarding testing strategies.Methods This cross-sectional descriptive study adopted a mixed method approach including desk reviews and key informant interviews (KIIs). The KIIs were conducted among actors of the COVID-19 response teams in states (SMoH) and the Federal Ministry of Health (FMoH) in Nigeria. Data extraction tools were populated from the relevant online resources and documents of the FMoH, SMoH and the Nigeria Centre for Disease Control.Results At the beginning of the pandemic in Nigeria, testing performance was poor, but this improved over time. To manage the demand for testing, Nigeria adopted targeted testing with a focus on symptomatic contacts and alerts, returning travelers from high-risk countries who were symptomatic during the quarantine period, among others groups. Strategies to enhance laboratory capacity and improve the turnaround time for results included leveraging on existing tuberculosis laboratory network or building new laboratories where none existed; decentralization of sample collection and testing; staff health workers repurposing and hiring of volunteers; training and retraining of laboratory personnel; adoption of rapid diagnostic testing; and strengthening public-private partnerships to leverage the private sector testing. From an initial three laboratories with capacity to test for SARS-CoV-2 in February, 2020, the number of laboratories increased to 158 by March, 2022. Although laboratory capacity increased, logistics and supply chain disruption was still a challenge.Conclusion Investment in local manufacturing capacities of laboratory consumables such as RDTs and reagents would promote self-reliance and sustainability for a country as populous as Nigeria.

show abstract

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study

Rumunu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Relatively few COVID-19 cases and deaths have been reported through much of sub-Saharan Africa, including South Sudan, although the extent of SARS-CoV-2 spread remains unclear due to weak surveillance systems and few population-representative serosurveys. Methods: We conducted a representative household-based cross-sectional serosurvey in Juba, South Sudan. We quantified IgG antibody responses to SARS-CoV-2 spike protein receptor-binding domain and estimated seroprevalence using a Bayesian regression model accounting for test performance. Results: We recruited 2,214 participants from August 10 to September 11, 2020 and 22.3% had anti-SARS-CoV-2 IgG titers above levels in pre-pandemic samples. After accounting for waning antibody levels, age, and sex, we estimated that 38.5% (32.1 - 46.8) of the population had been infected with SARS-CoV-2. For each RT-PCR confirmed COVID-19 case, 104 (87-126) infections were unreported. Background antibody reactivity was higher in pre-pandemic samples from Juba compared to Boston, where the serological test was validated. The estimated proportion of the population infected ranged from 30.1% to 60.6% depending on assumptions about test performance and prevalence of clinically severe infections. Conclusions: SARS-CoV-2 has spread extensively within Juba. Validation of serological tests in sub-Saharan African populations is critical to improve our ability to use serosurveillance to understand and mitigate transmission.

show abstract

Evaluation of SARS-CoV2 antibody Rapid Diagnostic Test kits (RDTs) and Real Time-Polymerase Chain Reaction (Rt-PCR) for COVID-19 Diagnosis in Kaduna, Nigeria

Cited by 3 publications

References 15 publications

Nigeria’s race to zero COVID-19 cases: True disease burden or testing failure?

Nigeria’s race to zero COVID-19 cases: True disease burden or testing failure?

Strategies for rapid scale up of laboratory capacity in a public health emergency in a resource-constrained setting: the SARS-CoV-2 Nigeria response experience

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study

Contact Info

Product

Resources

About